US75886F1075 - Common Stock
NASDAQ:REGN (11/28/2022, 12:16:30 PM)+10.77 (+1.46%)
|GICS Sector||Health Care|
|Earnings (Last)||11-03 2022-11-03/bmo||Earnings (Next)||02-02 2023-02-02|
|Ins Owners||1.94%||Inst Owners||85.6%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 10,368 full-time employees. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
777 Old Saw Mill River Road
Tarrytown NEW YORK 10591
CEO: Leonard S. Schleifer
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
A turnabout month left the market sitting on some nice gains. The next week's data might determine whether those gains hold.
They combine strong technicals and generally sound fundamentals.
/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy...
CytomX Therapeutics (CTMX) stock is rising higher on Wednesday after announcing a partnership with Regeneron Pharmaceuticals (REGN).
Here you can normally see the latest stock twits on REGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.